Mohs micrographic surgery for vulvar malignancies: A systematic review

Abstract

BCC, Basal cell carcinoma; BSC, basosquamous cell carcinoma; DFSP, dermatofibrosarcoma protuberans; DVT, deep vein thrombosis; EMPD, extramammary Paget disease; Gyn, gynecology; Gyn onc, gynecology oncology; n/a, not applicable; OBGYN, obstetrics and gynecology; Postop, postoperative; SCC, squamous cell carcinoma; VC, verrucous carcinoma. *Defect size was only reported in 2 cases. y In 3 of 107 cases, recurrence was not reported, and these were not included in the calculation of recurrence rate.

Pigmented vulvar basal cell carcinoma in a Hispanic patient treated with Mohs micrographic surgery

“…13 Our patient is the first pigmented vulvar BCC case reported in the literature that has been treated with MMS, an efficacious method for all vulvar malignancies. 12 No recurrences of vulvar BCC have been reported with MMS. 12 In summary, we present a case of a pigmented BCC on the vulva of an immunosuppressed Hispanic patient following a 3-year delay in diagnosis, which was treated with MMS, and review the current literature of other cases.…”

Inflammatory Vulvar Dermatoses (Part I)

“…5 Treatment is usually wide local excision or Mohs micrographic surgery. 6 Radiation, laser therapy, and topical therapies, such as imiquimod have also been used with variable success. 7,8 Systemic chemotherapy is utilized in advanced disease.…”

Vulvar squamous cell carcinoma guidelines do not include tissue-sparing techniques as a treatment option

“…For example, reports available on use of MMS for select cases of SCC have found this may be an effective modality as a first-line therapy in select cases and in some treatment-refractory cases: 38 cases of vulvar SCC were treated with MMS with 4 reporting recurrence, however most cases were not early SCC, as the average tumor size was 18 mm and multiple had been treated with prior modalities including excision. 4 Unfortunately, prospective studies on MMS for early vulvar SCC are lacking. Future studies should focus on efficacy and patient-reported outcomes with use of other tissue-sparing modalities for early vulvar SCC.…”